Amgen’s Rebate Bundling Makes It ‘Economically Unfeasible’ For Regeneron To Sell Praluent

Regeneron antitrust suit alleges Amgen’s bundling of Repatha rebates with Otezla and Enbrel has restricted Praluent’s market access and ability to compete with Repatha.